122 related articles for article (PubMed ID: 8725765)
1. Leuprolide acetate in advanced ovarian serous tumor of low malignant potential. A case report.
Tresukosol D; Kudelka AP; Edwards CL; Silva EG; Kanojia M; Kavanagh JJ
J Reprod Med; 1996 May; 41(5):363-6. PubMed ID: 8725765
[TBL] [Abstract][Full Text] [Related]
2. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion.
McKenney JK; Balzer BL; Longacre TA
Am J Surg Pathol; 2006 Oct; 30(10):1209-21. PubMed ID: 17001150
[TBL] [Abstract][Full Text] [Related]
3. Successful term pregnancy following conservative debulking surgery for a stage IIIA serous low-malignant-potential tumor of the ovary: a case report.
Miller DM; Ehlen TG; Saleh EA
Gynecol Oncol; 1997 Sep; 66(3):535-8. PubMed ID: 9299273
[TBL] [Abstract][Full Text] [Related]
4. Possible metaplastic origin of lymph node "metastases" in serous ovarian tumor of low malignant potential (borderline serous tumor).
Kadar N; Krumerman M
Gynecol Oncol; 1995 Dec; 59(3):394-7. PubMed ID: 8522262
[TBL] [Abstract][Full Text] [Related]
5. Hypersensitivity vasculitis associated with leuprolide (Lupron).
Gnanaraj J; Saif MW
Cutan Ocul Toxicol; 2010 Sep; 29(3):224-7. PubMed ID: 20470239
[TBL] [Abstract][Full Text] [Related]
6. Medical treatment of uterocutaneous fistula with gonadotropin-releasing hormone agonist administration.
Seyhan A; Ata B; Sidal B; Urman B
Obstet Gynecol; 2008 Feb; 111(2 Pt 2):526-8. PubMed ID: 18239009
[TBL] [Abstract][Full Text] [Related]
7. Metastatic serous borderline ovarian tumor in an internal mammary lymph node: a case report and review of the literature.
Chamberlin MD; Eltabbakh GH; Mount SL; Leavitt BJ
Gynecol Oncol; 2001 Jul; 82(1):212-5. PubMed ID: 11426990
[TBL] [Abstract][Full Text] [Related]
8. Molecular genetic evidence of an independent origin of serous low malignant potential implants and lymph node inclusions.
Emerson RE; Wang M; Liu F; Lawrence WD; Abdul-Karim FW; Cheng L
Int J Gynecol Pathol; 2007 Oct; 26(4):387-94. PubMed ID: 17885488
[TBL] [Abstract][Full Text] [Related]
9. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
10. Anastrozole therapy in recurrent ovarian adult granulosa cell tumors: a report of 2 cases.
Freeman SA; Modesitt SC
Gynecol Oncol; 2006 Nov; 103(2):755-8. PubMed ID: 16870240
[TBL] [Abstract][Full Text] [Related]
11. Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?
Cox MC; Scripture CD; Figg WD
Expert Rev Anticancer Ther; 2005 Aug; 5(4):605-11. PubMed ID: 16111462
[TBL] [Abstract][Full Text] [Related]
12. Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression.
Elkind-Hirsch KE; Anania C; Malinak R
J Reprod Med; 1996 Sep; 41(9):645-52. PubMed ID: 8887188
[TBL] [Abstract][Full Text] [Related]
13. Medical management of recurrent aggressive angiomyxoma with gonadotropin-releasing hormone agonist.
Shinohara N; Nonomura K; Ishikawa S; Seki H; Koyanagi T
Int J Urol; 2004 Jun; 11(6):432-5. PubMed ID: 15157218
[TBL] [Abstract][Full Text] [Related]
14. Postoperative long-term maintenance therapy with oral contraceptives after gonadotropin-releasing hormone analog treatment in women with ovarian endometrioma.
Park HJ; Koo YA; Yoon BK; Choi D
J Minim Invasive Gynecol; 2009; 16(1):34-9. PubMed ID: 18976968
[TBL] [Abstract][Full Text] [Related]
15. [Primary endocrine therapy as pre- and perimenopausal metastatic breast carcinoma with leuprorelin acetate depot. German Leuprorelin Study Group].
Untch M
Zentralbl Gynakol; 1998; 120(6):284-92. PubMed ID: 9659699
[TBL] [Abstract][Full Text] [Related]
16. Hormonal therapy in epithelial ovarian cancer.
Rao GG; Miller DS
Expert Rev Anticancer Ther; 2006 Jan; 6(1):43-7. PubMed ID: 16375643
[TBL] [Abstract][Full Text] [Related]
17. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
18. GnRH agonist for intravenous leiomyomatosis with cardiac extension. A case report.
Mitsuhashi A; Nagai Y; Sugita M; Nakajima N; Sekiya S
J Reprod Med; 1999 Oct; 44(10):883-6. PubMed ID: 10554751
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of leuprolide in advanced/recurrent endometrial cancer.
Covens A; Thomas G; Shaw P; Ackerman I; Osborne R; Lukka H; Carey M; Franssen E; Roche K
Gynecol Oncol; 1997 Jan; 64(1):126-9. PubMed ID: 8995560
[TBL] [Abstract][Full Text] [Related]
20. Lymphatic vascular invasion in ovarian serous tumors of low malignant potential with stromal microinvasion: a case control study.
Sangoi AR; McKenney JK; Dadras SS; Longacre TA
Am J Surg Pathol; 2008 Feb; 32(2):261-8. PubMed ID: 18223329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
